Vor Biopharma Inc. Financing Cash Flow
Vor Biopharma Inc. (VOR) reported Financing Cash Flow of $74.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Vor Biopharma Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$106.00K, a 100.06% decline year-over-year.
- Vor Biopharma Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $74.87M.
- Vor Biopharma Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $307.80M, a 477.64% increase year-over-year.
- Vor Biopharma Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $21.55M, a 52458.54% increase year-over-year.
- Vor Biopharma Inc. net cash provided by (used in) financing activities for fiscal 2025 was $503.81M, a 843.60% increase from fiscal 2024.
- Vor Biopharma Inc. net cash provided by (used in) financing activities for fiscal 2024 was $53.39M, a 1717.29% increase from fiscal 2023.
- Vor Biopharma Inc. net cash provided by (used in) financing activities for fiscal 2023 was $2.94M, a 97.49% decline from fiscal 2022.
- Vor Biopharma Inc. net cash provided by (used in) financing activities for fiscal 2022 was $117.14M, a 49.71% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $74.76M 10-Q · filed 2026-08-11 | $382.56M derived: sum of 3 quarters · filed 2026-08-11 | $404.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $74.87M 10-Q · filed 2026-05-13 | $382.67M derived: sum of 2 quarters · filed 2026-05-13 | $404.22M derived: sum of 3 quarters · filed 2026-05-13 | $579.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $307.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $329.35M derived: sum of 2 quarters · filed 2026-03-30 | $504.41M derived: sum of 3 quarters · filed 2026-08-11 | $503.81M 10-K · filed 2026-03-30 |
| 2025-09-30 | $21.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $196.61M derived: sum of 2 quarters · filed 2026-08-11 | $196.01M 10-Q · filed 2025-11-13 | $249.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $175.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $174.46M 10-Q · filed 2026-08-11 | $227.75M derived: sum of 3 quarters · filed 2026-08-11 | $227.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$606.00K 10-Q · filed 2026-05-13 | $52.68M derived: sum of 2 quarters · filed 2026-05-13 | $52.72M derived: sum of 3 quarters · filed 2026-05-13 | $52.69M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $53.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $53.33M derived: sum of 2 quarters · filed 2026-03-30 | $53.30M derived: sum of 3 quarters · filed 2026-03-30 | $53.39M 10-K · filed 2026-03-30 |
| 2024-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $10.00K derived: sum of 2 quarters · filed 2025-11-13 | $106.00K 10-Q · filed 2025-11-13 | $131.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $65.00K 10-Q · filed 2025-08-12 | $90.00K derived: sum of 3 quarters · filed 2025-08-12 | $266.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $96.00K 10-Q · filed 2025-05-14 | $121.00K derived: sum of 2 quarters · filed 2025-05-14 | $297.00K derived: sum of 3 quarters · filed 2025-05-14 | $515.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $201.00K derived: sum of 2 quarters · filed 2025-03-20 | $419.00K derived: sum of 3 quarters · filed 2025-03-20 | $2.94M 10-K · filed 2025-03-20 |
| 2023-09-30 | $176.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $394.00K derived: sum of 2 quarters · filed 2024-11-07 | $2.91M 10-Q · filed 2024-11-07 | $115.17M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $218.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.74M 10-Q · filed 2024-08-08 | $115.00M derived: sum of 3 quarters · filed 2024-08-08 | $119.07M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.52M 10-Q · filed 2024-05-09 | $114.78M derived: sum of 2 quarters · filed 2024-05-09 | $118.86M derived: sum of 3 quarters · filed 2024-05-09 | $119.46M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $112.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $116.34M derived: sum of 2 quarters · filed 2024-03-20 | $116.94M derived: sum of 3 quarters · filed 2024-03-20 | $117.14M 10-K · filed 2024-03-20 |
| 2022-09-30 | $4.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $4.68M derived: sum of 2 quarters · filed 2023-11-07 | $4.88M 10-Q · filed 2023-11-07 | $5.19M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $604.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $804.00K 10-Q · filed 2023-08-10 | $1.11M derived: sum of 3 quarters · filed 2023-08-10 | $1.31M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-11 | $507.00K derived: sum of 2 quarters · filed 2023-05-11 | $708.00K derived: sum of 3 quarters · filed 2023-05-11 | $263.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $307.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $508.00K derived: sum of 2 quarters · filed 2023-03-23 | $63.00K derived: sum of 3 quarters · filed 2023-03-23 | $232.91M 10-K · filed 2023-03-23 |
| 2021-09-30 | $201.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$244.00K derived: sum of 2 quarters · filed 2022-11-10 | $232.60M 10-Q · filed 2022-11-10 | $232.65M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$445.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $232.40M 10-Q · filed 2022-08-11 | $232.45M derived: sum of 3 quarters · filed 2022-08-11 | $232.97M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $232.85M 10-Q · filed 2022-05-12 | $232.89M derived: sum of 2 quarters · filed 2022-05-12 | $233.42M derived: sum of 3 quarters · filed 2022-05-12 | $297.61M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $572.00K derived: sum of 2 quarters · filed 2022-03-14 | $64.76M derived: sum of 3 quarters · filed 2022-03-14 | $82.53M 10-K · filed 2022-03-14 |
| 2020-09-30 | $526.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $64.72M derived: sum of 2 quarters · filed 2021-11-10 | $82.48M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $64.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $81.95M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $17.76M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |